Bomanji J, Hungerford J L, Kingston J E, Levison D A, Britton K E
Department of Nuclear Medicine, St Bartholomew's Hospital, London.
Br J Ophthalmol. 1989 Feb;73(2):146-50. doi: 10.1136/bjo.73.2.146.
123I metaiodobenzylguanidine (MIBG) is a radiopharmaceutical used for imaging neural crest tumours. The possibility of using 123I MIBG for imaging retinoblastomas has been assessed in this pilot study. Ten patients were studied, nine with clinically and histologically proved retinoblastomas and one with Coats's disease. 123I MIBG scintigraphy correctly identified the neoplasm in eight patients but gave a negative result in two, one of whom had Coats's disease and the other a retinoblastoma which proved to be extensively necrotic on histological examination. These preliminary results suggest that 123I MIBG scintigraphy may have a role in differentiating retinoblastomas from lesions that simulate them.
123I间碘苄胍（MIBG）是一种用于神经嵴肿瘤成像的放射性药物。本初步研究评估了使用123I MIBG对视网膜母细胞瘤进行成像的可能性。研究了10例患者，其中9例经临床和组织学证实为视网膜母细胞瘤，1例患有科茨病。123I MIBG闪烁扫描正确识别了8例患者的肿瘤，但2例结果为阴性，其中1例患有科茨病，另1例为视网膜母细胞瘤，组织学检查显示广泛坏死。这些初步结果表明，123I MIBG闪烁扫描可能在鉴别视网膜母细胞瘤与类似病变方面发挥作用。
